Please log in to access this page.

Imfinzi and Pneumothorax - a phase IV clinical study of FDA data

Summary:

Pneumothorax is reported as a side effect among people who take Imfinzi (durvalumab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Xalatan, and have Lung cancer - non-small cell.

The phase IV clinical study analyzes which people have Pneumothorax when taking Imfinzi. It is created by eHealthMe based on reports of 8,352 people who have side effects when taking Imfinzi from the FDA, and is updated regularly.

What is Imfinzi?

Imfinzi has active ingredients of durvalumab. eHealthMe is studying from 8,353 Imfinzi users. Check the latest studies of Imfinzi.

What is Pneumothorax?

Pneumothorax (the presence of air or gas in the cavity between the lungs and the chest wall, causing collapse of the lung) is found to be associated with 1,231 drugs and 1,346 conditions by eHealthMe. Check the latest studies of Pneumothorax.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Jul, 02, 2026

8,352 people reported to have side effects when taking Imfinzi.
Among them, 58 people (0.69%) have Pneumothorax.

Could Imfinzi cause Pneumothorax?

Among these 58 people:

How long have people been on Imfinzi when they have Pneumothorax? *

  • < 1 month: 73.33 %
  • 1 - 6 months: 23.33 %
  • 6 - 12 months: 3.33 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Pneumothorax when taking Imfinzi? *

  • female: 7.55 %
  • male: 92.45 %

What is the age of people who have Pneumothorax when taking Imfinzi? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 6.12 %
  • 60+: 93.88 %

What are other drugs people take besides Imfinzi? *

  1. Amlodipine: 3 people, 5.17%
  2. Nexium: 3 people, 5.17%
  3. Lipitor: 3 people, 5.17%
  4. Xalatan: 3 people, 5.17%
  5. Acetaminophen: 2 people, 3.45%
  6. Etoposide: 2 people, 3.45%
  7. Carboplatin: 2 people, 3.45%
  8. Magnesium Oxide: 2 people, 3.45%
  9. Lunesta: 2 people, 3.45%
  10. Belsomra: 1 person, 1.72%

What are other side effects people have besides Pneumothorax? *

  1. Radiation Pneumonitis (inflammation of lung due to radiation): 24 people, 41.38%
  2. Pneumonia: 16 people, 27.59%
  3. Interstitial Lung Disease: 10 people, 17.24%
  4. Malignant Neoplasm Progression (cancer tumour came back): 5 people, 8.62%
  5. Infectious Pleural Effusion (infectious fluid in the lung): 4 people, 6.90%
  6. Pleural Effusion (water on the lungs): 4 people, 6.90%
  7. Death: 3 people, 5.17%
  8. Liver Disorder (liver diseases): 3 people, 5.17%
  9. Herpes Zoster: 3 people, 5.17%
  10. Pneumonia Aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree): 3 people, 5.17%

What are the existing conditions these people have? *

  1. Lung Cancer - Non-Small Cell (lung cancer): 41 people, 70.69%
  2. Hyperlipidaemia (presence of excess lipids in the blood): 6 people, 10.34%
  3. High Blood Pressure: 5 people, 8.62%
  4. Radiation Pneumonitis (inflammation of lung due to radiation): 3 people, 5.17%
  5. Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 3 people, 5.17%
  6. Heart Attack: 3 people, 5.17%
  7. Glaucoma (increased fluid pressure in the eye with vision loss): 3 people, 5.17%
  8. Lung Cancer - Small Cell (lung cancer): 3 people, 5.17%
  9. Small Cell Lung Cancer Extensive Stage (small cell lung cancer that has spread (metastasized) to other regions of the body such as another lobe of the lung or the brain): 2 people, 3.45%
  10. Non-Small Cell Lung Cancer Stage Iv: 2 people, 3.45%

* Approximation only. Some reports may have incomplete information.

Do you take Imfinzi and have Pneumothorax?

- Check whether Pneumothorax is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, long term effects of, and alternative drugs to Imfinzi:

Pneumothorax treatments and more:

How severe was Pneumothorax and when was it recovered:

Expand to all the drugs that have ingredients of durvalumab:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Imfinzi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pneumothorax:

Browse all the conditions that are associated with Pneumothorax:


How the study uses the data?

The study uses data from the FDA. It is based on durvalumab (the active ingredients of Imfinzi) and Imfinzi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: